Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

Sanofi’s $1.76 billion acquisition of Vicebio has delivers a windfall for the University of Queensland — and highlighted a ...

Sanofi acquires UQ-linked biotech Vicebio for up to US$1.6b, marking Australia’s largest university commercialisation deal.

Health care companies recouped some of their recent losses amid generally strong earnings and deal activity. British drug maker AstraZeneca said it plans to invest $50 billion in the U.S. by 2030, ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

A lawsuit filed in federal court on behalf of the University of Pennsylvania and its health system alleges that 20 years of skyrocketing prices on drugs that treat diabetes, like insulin, can be ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly ...